Resumen

APARICIO HERNANDEZ, R; GARCIA LUQUE, A; PEREZ MORAN, MªJ  y  CABANES MARISCAL, MªA. Possitive assesment of drugs: March and April 2018. Sanid. Mil. [online]. 2018, vol.74, n.3, pp.163-167. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712018000300005.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in March, April and May of 2018, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palabras clave : Bictegravir/Emtricitabina/Tenofovir alafenamida, Biktarvy®; Dolutegravir/Rilpivirina, Juluca®; Infliximab, Zessly®; Rucaparib, Rubraca®; Sufentanilo, Dzuveo®; Trastuzumab, Kanjinti®..

        · resumen en Español     · texto en Español     · Español ( pdf )